Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Sergio Jobim de Azevedo,Delphine Borchiellini,Raymond S. McDermott,Jens Bedke,Satoshi Tamada,Shuyan Sabrina Wan,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

2019

4500Background: In KEYNOTE-426, pembro + axi significantly improved OS (HR 0.53, P < .0001), PFS (HR 0.69, P = .0001), and ORR (59.3% vs 35.7%, P < .0001) vs sunitinib and had manageable toxicity a...

Keywords:

Oncology
Renal cell carcinoma
Pathology
Axitinib
Pembrolizumab
Internal medicine
Sunitinib
Medicine
first line therapy
Toxicity
poor risk

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations